China's medicine regulator is reviewing a second domestically developed COVID-19 vaccine for conditional approval.
The CoronaVac inoculation, developed by Sinovac Biotech, has been given to tens of thousands of people in China under an emergency use program launched in July targeting specific groups with high infection risks. Regulators are also reviewing for approval a similar vaccine created by state-owned China National Pharmaceutical Group, known as Sinopharm.